Thermidas: A Breakthrough in Non-Invasive Skin Temperature Measurement

By HEOR Staff Writer

August 21, 2023

FinCCHTA, the Finnish Coordinating Centre for Health Technology Assessment, has recommended the use of Thermidas, a non-invasive thermal imaging system, to support diagnostics and monitor treatment. The system, which includes imaging analysis and reporting software, is particularly useful for measuring skin surface temperature changes.

Thermidas has been shown to be effective in monitoring temperature differences, indicating changes in the circulatory index, subclinical infections, the severity of vascular disease, and specific complications of Charcot neuro-osteoarthropathy. It has also been found to be a reliable and reproducible method for measuring temperature across areas, compared to traditional point-like temperature measurements in healthy adults.

The system has been particularly beneficial in the monitoring of diabetic foot ulcers and rheumatoid arthritis. A study demonstrated that infrared thermal imaging was able to detect temperature differences in the feet of a group of patients at high risk due to diabetes. Another cross-sectional study showed that combined thermal and ultrasound imaging provides better information about the area under examination than either imaging method used alone in assessing arthritis in rheumatoid arthritis cases.

The Thermidas system is recommended for use until April 2026. The manufacturer has provided evidence of theoretical cost savings, particularly in the monitoring of diabetic podiatric conditions and inflammatory rheumatoid arthritis, as well as in support of diagnostics. The purchase price of the system includes deployment training, with post-acquisition product and maintenance support subject to a fee. 

Reference url

Recent Posts

Enhancing Health Technology Assessment Transparency through Digital Innovation

By João L. Carapinha

April 30, 2026

Portugal’s national medicines agency is using digital innovation to bring greater openness to health technology assessment. INFARMED, I.P. has released a new public platform called “Tracker de Processos” that allows anyone to follow, in real time, the progress of funding and reimbursement applica...
Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometabolic Care
Merck’s first-quarter 2026 results have been published and highlight key growth drivers, regulatory achievements, and strategic moves that reinforce the company’s diversified portfolio. Oncology Dominance Fueled by KEYTRUDA Expansion Merck Q1 2026 performance was prima...
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO 2026
Johnson & Johnson is driving progress in high-risk oncology interventions through more than 20 clinical and real-world studies presented at the 2026 ASCO Annual Meeting. By focusing on earlier therapeutic intervention and precision regimens, the company aims to improve outcomes in prostate ca...